APA (7th ed.) Citation

Mittlmeier, L. M., Unterrainer, M., Todica, A., Cyran, C. C., Rodler, S., Bartenstein, P., . . . Staehler, M. (2020). PSMA PET/CT for tyrosine-kinase inhibitor monitoring in metastatic renal cell carcinoma. European Journal of Nuclear Medicine & Molecular Imaging, 47(9), 2216. https://doi.org/10.1007/s00259-019-04636-6

Chicago Style (17th ed.) Citation

Mittlmeier, L. M., M. Unterrainer, A. Todica, C. C. Cyran, S. Rodler, P. Bartenstein, C. G. Stief, H. Ilhan, and M. Staehler. "PSMA PET/CT for Tyrosine-kinase Inhibitor Monitoring in Metastatic Renal Cell Carcinoma." European Journal of Nuclear Medicine & Molecular Imaging 47, no. 9 (2020): 2216. https://doi.org/10.1007/s00259-019-04636-6.

MLA (9th ed.) Citation

Mittlmeier, L. M., et al. "PSMA PET/CT for Tyrosine-kinase Inhibitor Monitoring in Metastatic Renal Cell Carcinoma." European Journal of Nuclear Medicine & Molecular Imaging, vol. 47, no. 9, 2020, p. 2216, https://doi.org/10.1007/s00259-019-04636-6.